A Phase 3 Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Adults at High Risk of Delayed Graft Function (DGF) Following Kidney Allograft Transplantation

NCT07020832 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

320

Enrollment

INDUSTRY

Sponsor class

Conditions

Delayed Graft Function
End Stage Renal Disease
Deceased Donor Kidney Transplant

Interventions

DRUG: Pegcetacoplan
OTHER: Placebo

Sponsor

Apellis Pharmaceuticals, Inc.